Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06181786 · ClinicalTrials.gov registry record · Phase 1
Study of NAV-240 in Healthy Volunteers
A Phase 1 study, sponsored by Navigator Medicines.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT06181786 is a Phase 1 study that has completed, run by Navigator Medicines. The registered enrollment target is 40 participants.
The verdict
NCT06181786, a Phase 1 study, has completed, sponsored by Navigator Medicines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of intravenous (IV) doses of NAV-240 in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG NAV-240
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-11-22 |
| Est. Completion | 2024-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06181786
The ClinicalTrials.gov registry entry for NCT06181786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navigator Medicines, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06181786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06181786 about?
NCT06181786 is a clinical study titled "Study of NAV-240 in Healthy Volunteers". The primary purpose of this study is to evaluate the safety and tolerability of intravenous (IV) doses of NAV-240 in healthy volunteers.
What is the current status of trial NCT06181786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-11-22. Estimated completion is 2024-09-04.
What interventions are being tested in trial NCT06181786?
The interventions under investigation include: Placebo (DRUG), NAV-240 (DRUG).
Who is sponsoring clinical trial NCT06181786?
This trial is sponsored by Navigator Medicines, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.